|
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
20 results found
| no | title | author | magazine | year | volume | issue | page(s) | type |
| 1 | ADMA and hyperhomocysteinemia |
Dayal, Sanjana |
2005 |
vmr-6 | 1_suppl |
p. S27-S33 |
article |
|
| 2 | ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study |
Böger, Rainer H |
2005 |
vmr-6 | 1_suppl |
p. S97-S102 |
article |
|
| 3 | ADMA: an emerging cardiovascular risk factor |
Böger, Rainer H |
2005 |
vmr-6 | 1_suppl |
p. S1-S2 |
article |
|
| 4 | ADMA: its role in vascular disease |
Cooke, John P |
2005 |
vmr-6 | 1_suppl |
p. S11-S17 |
article |
|
| 5 | ADMA metabolism and clearance |
Teerlink, Tom |
2005 |
vmr-6 | 1_suppl |
p. S73-S81 |
article |
|
| 6 | Angiogenesis/vasculogenesis |
2006 |
vmr-6 | 1_suppl |
p. S1-S17 |
article |
||
| 7 | Arginine metabolism in vascular biology and disease |
Morris, Sidney M |
2005 |
vmr-6 | 1_suppl |
p. S83-S87 |
article |
|
| 8 | Asymmetric dimethylarginine (ADMA) accelerates cell senescence |
Bode-Böger, Stefanie M |
2005 |
vmr-6 | 1_suppl |
p. S65-S71 |
article |
|
| 9 | Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials |
Böger, Rainer H |
2005 |
vmr-6 | 1_suppl |
p. S19-S25 |
article |
|
| 10 | Atherothrombosis - the neurologist’s point of view |
Leys, Didier |
2001 |
vmr-6 | 1_suppl |
p. 17-19 |
article |
|
| 11 | DDAH gene and cardiovascular risk |
Valkonen, Veli-Pekka |
2005 |
vmr-6 | 1_suppl |
p. S45-S48 |
article |
|
| 12 | Endogenous production of nitric oxide synthase inhibitors |
Anthony, Shelagh |
2005 |
vmr-6 | 1_suppl |
p. S3-S9 |
article |
|
| 13 | Foreword |
Belch, Jill |
2001 |
vmr-6 | 1_suppl |
p. 1 |
article |
|
| 14 | Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA |
Sydow, Karsten |
2005 |
vmr-6 | 1_suppl |
p. S35-S43 |
article |
|
| 15 | PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program |
Hirsch, Alan T |
2001 |
vmr-6 | 1_suppl |
p. 9-12 |
article |
|
| 16 | Peripheral arterial disease - epidemiological aspects |
Criqui, Michael H |
2001 |
vmr-6 | 1_suppl |
p. 3-7 |
article |
|
| 17 | Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) |
Maas, Renke |
2005 |
vmr-6 | 1_suppl |
p. S49-S57 |
article |
|
| 18 | Quantification of ADMA: analytical approaches |
Schwedhelm, Edzard |
2005 |
vmr-6 | 1_suppl |
p. S89-S95 |
article |
|
| 19 | Rationale for the use of platelet aggregation inhibitors in PAD patients |
Agnelli, Giancarlo |
2001 |
vmr-6 | 1_suppl |
p. 13-15 |
article |
|
| 20 | Spotlight on endothelial progenitor cell inhibitors: short review |
Thum, Thomas |
2005 |
vmr-6 | 1_suppl |
p. S59-S64 |
article |
20 results found